| http://dbpedia.org/ontology/abstract
|
Drinabant (INN; AVE-1625) es un fármaco qu … Drinabant (INN; AVE-1625) es un fármaco que actúa como un selectivo de CB1 antagonista, que estaba bajo investigación por Sanofi-Aventis como un tratamiento para la obesidad, la esquizofrenia, la enfermedad de Alzheimer, enfermedad de Parkinson, y dependencia de la nicotina. Aunque estudiada inicialmente como un posible tratamiento para una variedad de diferentes condiciones médicas , Sanofi-Aventis, finalmente, redujo las terapéuticas indicaciones del compuesto para solo la supresión del apetito . Drinabant alcanzó fase IIb de ensayos clínicos para esta finalidad en el tratamiento de la obesidad, pero fue poco después suspendida, probablemente debido a la observación de graves efectos psiquiátricos secundarios incluyendo la ansiedad, la depresión y los pensamientos suicidas en pacientes tratados con la retirada de Rimonabant, otro OC 1 antagonista que también estaba siendo desarrollado por Sanofi-Aventis.a siendo desarrollado por Sanofi-Aventis.
, Drinabant (INN; AVE-1625) is a drug that a … Drinabant (INN; AVE-1625) is a drug that acts as a selective CB1 receptor antagonist, which was under investigation varyingly by Sanofi-Aventis as a treatment for obesity, schizophrenia, Alzheimer's disease, Parkinson's disease, and nicotine dependence. Though initially studied as a potential treatment for a variety of different medical conditions, Sanofi-Aventis eventually narrowed down the therapeutic indications of the compound to just appetite suppression. Drinabant reached phase IIb clinical trials for this purpose in the treatment of obesity but was shortly thereafter discontinued, likely due to the observation of severe psychiatric side effects including anxiety, depression, and thoughts of suicide in patients treated with the now-withdrawn rimonabant, another CB1 antagonist that was also under development by Sanofi-Aventis. In late 2018, the drug was licensed by Opiant Pharmaceuticals, which intends to develop it for the treatment of (ACO) as an injectable for administration in an emergency department setting. Opiant claims that ACO is most frequently linked to the ingestion of edibles containing large quantities THC and synthetic cannabinoids that are more potent and less expensive than marijuana. Edibles, sold as brownies, cookies and candies, pose particular risks for children, who often consume these by accident. There are currently no approved treatments for ACO. currently no approved treatments for ACO.
|
| http://dbpedia.org/ontology/casNumber
|
358970-97-5
|
| http://dbpedia.org/ontology/fdaUniiCode
|
61S98RLL5I
|
| http://dbpedia.org/ontology/pubchem
|
10278470
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Drinabant.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageID
|
35805433
|
| http://dbpedia.org/ontology/wikiPageLength
|
5027
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1075450677
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/CB1_receptor +
, http://dbpedia.org/resource/THC +
, http://dbpedia.org/resource/Category:Sulfonamides +
, http://dbpedia.org/resource/Major_depression +
, http://dbpedia.org/resource/Obesity +
, http://dbpedia.org/resource/Rimonabant +
, http://dbpedia.org/resource/Nicotine_dependence +
, http://dbpedia.org/resource/Clinical_trial +
, http://dbpedia.org/resource/Schizophrenia +
, http://dbpedia.org/resource/Category:Cannabinoids +
, http://dbpedia.org/resource/Side_effect +
, http://dbpedia.org/resource/Receptor_antagonist +
, http://dbpedia.org/resource/Medical_condition +
, http://dbpedia.org/resource/Binding_selectivity +
, http://dbpedia.org/resource/Cannabis_edible +
, http://dbpedia.org/resource/Indication_%28medicine%29 +
, http://dbpedia.org/resource/Phases_of_clinical_research +
, http://dbpedia.org/resource/Therapy +
, http://dbpedia.org/resource/Psychiatric +
, http://dbpedia.org/resource/Parkinson%27s_disease +
, http://dbpedia.org/resource/Category:CB1_receptor_antagonists +
, http://dbpedia.org/resource/Category:Azetidines +
, http://dbpedia.org/resource/Sanofi-Aventis +
, http://dbpedia.org/resource/Drug +
, http://dbpedia.org/resource/Anxiety +
, http://dbpedia.org/resource/Category:Anorectics +
, http://dbpedia.org/resource/Suicidal_ideation +
, http://dbpedia.org/resource/Alzheimer%27s_disease +
, http://dbpedia.org/resource/Category:Chlorobenzenes +
, http://dbpedia.org/resource/Cannabinoid_receptor_antagonist +
, http://dbpedia.org/resource/Category:Fluoroarenes +
, http://dbpedia.org/resource/Appetite_suppressant +
, http://dbpedia.org/resource/Acute_cannabinoid_overdose +
, http://dbpedia.org/resource/Withdrawn_drug +
, http://dbpedia.org/resource/International_Nonproprietary_Name +
, http://dbpedia.org/resource/Synthetic_cannabinoids +
|
| http://dbpedia.org/property/atcPrefix
|
None
|
| http://dbpedia.org/property/c
|
23
|
| http://dbpedia.org/property/casNumber
|
358970
|
| http://dbpedia.org/property/chemspiderid
|
8453947
|
| http://dbpedia.org/property/cl
|
2
|
| http://dbpedia.org/property/f
|
2
|
| http://dbpedia.org/property/h
|
20
|
| http://dbpedia.org/property/image
|
Drinabant ball-and-stick model.png
|
| http://dbpedia.org/property/iupacName
|
-N-{1-[Bismethyl]-3-azetidinyl}-N-methanesulfonamide
|
| http://dbpedia.org/property/legalStatus
|
Development terminated
|
| http://dbpedia.org/property/n
|
2
|
| http://dbpedia.org/property/o
|
2
|
| http://dbpedia.org/property/pubchem
|
10278470
|
| http://dbpedia.org/property/s
|
1
|
| http://dbpedia.org/property/smiles
|
Fc1ccNSC
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
IQQBRKLVEALROM-UHFFFAOYSA-N
|
| http://dbpedia.org/property/unii
|
61
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Anorectics +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Cannabinoidergics +
, http://dbpedia.org/resource/Template:Cannabinoids +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Fluoroarenes +
, http://dbpedia.org/resource/Category:Azetidines +
, http://dbpedia.org/resource/Category:Cannabinoids +
, http://dbpedia.org/resource/Category:CB1_receptor_antagonists +
, http://dbpedia.org/resource/Category:Sulfonamides +
, http://dbpedia.org/resource/Category:Anorectics +
, http://dbpedia.org/resource/Category:Chlorobenzenes +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Drug +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Drinabant?oldid=1075450677&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Drinabant.svg +
, http://commons.wikimedia.org/wiki/Special:FilePath/Drinabant_ball-and-stick_model.png +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Drinabant +
|
| owl:sameAs |
http://azb.dbpedia.org/resource/%D8%AF%D8%B1%DB%8C%D9%86%D8%A7%D8%A8%D8%A7%D9%86%D8%AA +
, https://global.dbpedia.org/id/4ipwm +
, http://dbpedia.org/resource/Drinabant +
, http://www.wikidata.org/entity/Q5307675 +
, http://sh.dbpedia.org/resource/Drinabant +
, http://fa.dbpedia.org/resource/%D8%AF%D8%B1%DB%8C%D9%86%D8%A7%D8%A8%D8%A7%D9%86%D8%AA +
, http://rdf.freebase.com/ns/m.0jt0g5g +
, http://yago-knowledge.org/resource/Drinabant +
, http://es.dbpedia.org/resource/Drinabant +
, http://sr.dbpedia.org/resource/Drinabant +
|
| rdf:type |
http://dbpedia.org/class/yago/SickPerson110595647 +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/class/yago/Anorexic109795751 +
, http://dbpedia.org/class/yago/Whole100003553 +
, http://dbpedia.org/class/yago/WikicatAnorectics +
, http://dbpedia.org/class/yago/Message106598915 +
, http://dbpedia.org/class/yago/Statement106722453 +
, http://dbpedia.org/class/yago/Person100007846 +
, http://dbpedia.org/class/yago/Object100002684 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/WikicatCB1ReceptorAntagonists +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/Unfortunate109630641 +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/Adversary109773245 +
, http://dbpedia.org/class/yago/Organism100004475 +
, http://dbpedia.org/class/yago/WikicatMolecularFormulas +
, http://dbpedia.org/class/yago/LivingThing100004258 +
, http://dbpedia.org/class/yago/MolecularFormula106817173 +
, http://dbpedia.org/class/yago/Formula106816935 +
, http://dbpedia.org/class/yago/YagoLegalActorGeo +
, http://dbpedia.org/class/yago/YagoLegalActor +
, http://dbpedia.org/class/yago/Communication100033020 +
, http://dbpedia.org/class/yago/CausalAgent100007347 +
|
| rdfs:comment |
Drinabant (INN; AVE-1625) is a drug that a … Drinabant (INN; AVE-1625) is a drug that acts as a selective CB1 receptor antagonist, which was under investigation varyingly by Sanofi-Aventis as a treatment for obesity, schizophrenia, Alzheimer's disease, Parkinson's disease, and nicotine dependence. Though initially studied as a potential treatment for a variety of different medical conditions, Sanofi-Aventis eventually narrowed down the therapeutic indications of the compound to just appetite suppression. Drinabant reached phase IIb clinical trials for this purpose in the treatment of obesity but was shortly thereafter discontinued, likely due to the observation of severe psychiatric side effects including anxiety, depression, and thoughts of suicide in patients treated with the now-withdrawn rimonabant, another CB1 antagonist that warimonabant, another CB1 antagonist that wa
, Drinabant (INN; AVE-1625) es un fármaco qu … Drinabant (INN; AVE-1625) es un fármaco que actúa como un selectivo de CB1 antagonista, que estaba bajo investigación por Sanofi-Aventis como un tratamiento para la obesidad, la esquizofrenia, la enfermedad de Alzheimer, enfermedad de Parkinson, y dependencia de la nicotina. Aunque estudiada inicialmente como un posible tratamiento para una variedad de diferentes condiciones médicas , Sanofi-Aventis, finalmente, redujo las terapéuticas indicaciones del compuesto para solo la supresión del apetito . Drinabant alcanzó fase IIb de ensayos clínicos para esta finalidad en el tratamiento de la obesidad, pero fue poco después suspendida, probablemente debido a la observación de graves efectos psiquiátricos secundarios incluyendo la ansiedad, la depresión y los pensamientos suicidas en pacientes y los pensamientos suicidas en pacientes
|
| rdfs:label |
Drinabant
|
